Poseida Therapeutics, Inc.

DB:2RZ Stock Report

Market Cap: €879.0m

Poseida Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

DB:2RZ Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
26 Nov 24Buy€23,536,481Pentwater Capital Management LPCompany2,650,000€8.88

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 2RZ?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders6,625,2696.8%
Hedge Funds8,625,0008.85%
General Public13,682,55714%
Public Companies20,169,00620.7%
Institutions48,364,83449.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 79.72% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15%
FMR LLC
14,570,078€131.4m0.18%0.01%
12.1%
Malin Corporation plc
11,835,673€106.7m0%no data
8.85%
Pentwater Capital Management LP
8,625,000€77.8m44.4%1.59%
8.55%
Astellas Pharma Inc.
8,333,333€75.2m0%no data
6.19%
Eric Ostertag
6,028,560€54.4m0%no data
5.26%
BlackRock, Inc.
5,123,969€46.2m4.46%no data
3.78%
Silverarc Capital Management, LLC
3,687,548€33.3m2.2%7.96%
3.76%
The Vanguard Group, Inc.
3,663,456€33.0m7.57%no data
2.25%
Millennium Management LLC
2,193,755€19.8m241%0.02%
2.05%
Tavistock Life Sciences
2,000,000€18.0m-55.3%1.28%
1.76%
State Street Global Advisors, Inc.
1,710,565€15.4m2.32%no data
1.66%
Geode Capital Management, LLC
1,617,137€14.6m-0.34%no data
1.14%
William Blair Investment Management, LLC
1,112,140€10.0m0.98%0.01%
1.07%
Aisling Capital Management LP
1,043,267€9.4m0%3.47%
0.92%
Renaissance Technologies LLC
897,603€8.1m5%0.01%
0.85%
Acadian Asset Management LLC
831,041€7.5m108%0.02%
0.83%
Jacobs Levy Equity Management Inc
811,512€7.3m-12.5%0.03%
0.58%
Charles Schwab Investment Management, Inc.
567,063€5.1m3.89%no data
0.58%
Northern Trust Global Investments
565,387€5.1m3.49%no data
0.58%
Dimensional Fund Advisors LP
563,135€5.1m-6.11%no data
0.49%
Woodline Partners LP
478,861€4.3m0%0.04%
0.42%
Goldman Sachs Asset Management, L.P.
406,134€3.7m6.88%no data
0.37%
Connor, Clark & Lunn Investment Management Ltd.
359,197€3.2m62.8%0.02%
0.36%
Arrowstreet Capital, Limited Partnership
351,366€3.2m0%no data
0.33%
AQR Capital Management, LLC
324,055€2.9m526%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 13:44
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Poseida Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Justin ZelinBTIG
Jennifer KimCantor Fitzgerald & Co.